Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study

Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Amarenco, Pierre (VerfasserIn) , Bogousslavsky, Julien (VerfasserIn) , Callahan, Alfred S. (VerfasserIn) , Goldstein, Larry (VerfasserIn) , Hennerici, Michael G. (VerfasserIn) , Sillsen, Henrik (VerfasserIn) , Welch, Michael A. (VerfasserIn) , Zivin, Justin A. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: September 19, 2003
In: Cerebrovascular diseases
Year: 2003, Jahrgang: 16, Heft: 4, Pages: 389-395
ISSN:1421-9786
DOI:10.1159/000072562
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000072562
Volltext
Verfasserangaben:the SPARCL Investigators

MARC

LEADER 00000caa a2200000 c 4500
001 1805529285
003 DE-627
005 20230428181741.0
007 cr uuu---uuuuu
008 220601s2003 xx |||||o 00| ||eng c
024 7 |a 10.1159/000072562  |2 doi 
035 |a (DE-627)1805529285 
035 |a (DE-599)KXP1805529285 
035 |a (OCoLC)1341460596 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Amarenco, Pierre  |e VerfasserIn  |0 (DE-588)1155322851  |0 (DE-627)1016735049  |0 (DE-576)50154657X  |4 aut 
245 1 0 |a Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study  |c the SPARCL Investigators 
264 1 |c September 19, 2003 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Prepared by the SPARCL Publications Committee for the SPARCL Investigators: Pierre Amarenco, Julien Bogousslavsky, Alfred S. Callahan, Larry Goldstein, Michael Hennerici, Henrik Sillsen, Michael A. Welch, Justin Zivin 
500 |a Gesehen am 01.06.2022 
520 |a Evidence suggests that statin therapy reduces the risk of stroke in patients with coronary heart disease (CHD), but its benefit for patients with cerebrovascular disease and no history of CHD remains uncertain. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study is a prospective, multi-centre, double-blind, randomised, placebo-controlled trial designed to evaluate the effects of atorvastatin 80 mg/day in patients who previously experienced a stroke or transient ischaemic attack, but who have no known CHD. A total of 4732 patients have been enrolled, and the data collection phase of the study is expected to be completed by October 2004. SPARCL is the first study primarily designed to prospectively evaluate the effect of statin treatment in secondary stroke prevention. 
650 4 |a Adult 
650 4 |a Aged 
650 4 |a Aged, 80 and over 
650 4 |a Atorvastatin 
650 4 |a Cholesterol 
650 4 |a Double-Blind Method 
650 4 |a Endpoint Determination 
650 4 |a Female 
650 4 |a Heptanoic Acids 
650 4 |a Humans 
650 4 |a Hydroxymethylglutaryl-CoA Reductase Inhibitors 
650 4 |a Male 
650 4 |a Middle Aged 
650 4 |a Multicenter Studies as Topic 
650 4 |a Patient Selection 
650 4 |a Prospective Studies 
650 4 |a Pyrroles 
650 4 |a Randomized Controlled Trials as Topic 
650 4 |a Research Design 
650 4 |a Secondary Prevention 
650 4 |a Stroke 
700 1 |a Bogousslavsky, Julien  |d 1954-  |e VerfasserIn  |0 (DE-588)131879588  |0 (DE-627)515959405  |0 (DE-576)169792781  |4 aut 
700 1 |a Callahan, Alfred S.  |e VerfasserIn  |4 aut 
700 1 |a Goldstein, Larry  |e VerfasserIn  |4 aut 
700 1 |a Hennerici, Michael G.  |d 1948-  |e VerfasserIn  |0 (DE-588)11587545X  |0 (DE-627)077527704  |0 (DE-576)290126444  |4 aut 
700 1 |a Sillsen, Henrik  |e VerfasserIn  |4 aut 
700 1 |a Welch, Michael A.  |e VerfasserIn  |4 aut 
700 1 |a Zivin, Justin A.  |e VerfasserIn  |0 (DE-588)104608609X  |0 (DE-627)775702293  |0 (DE-576)399374469  |4 aut 
773 0 8 |i Enthalten in  |t Cerebrovascular diseases  |d Basel : Karger, 1991  |g 16(2003), 4, Seite 389-395  |h Online-Ressource  |w (DE-627)300189834  |w (DE-600)1482069-9  |w (DE-576)097267651  |x 1421-9786  |7 nnas  |a Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study 
773 1 8 |g volume:16  |g year:2003  |g number:4  |g pages:389-395  |g extent:7  |a Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study 
856 4 0 |u https://doi.org/10.1159/000072562  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220601 
993 |a Article 
994 |a 2003 
998 |g 11587545X  |a Hennerici, Michael G.  |m 11587545X:Hennerici, Michael G.  |d 910000  |d 911100  |d 60000  |e 910000PH11587545X  |e 911100PH11587545X  |e 60000PH11587545X  |k 0/910000/  |k 1/910000/911100/  |k 0/60000/  |p 5 
999 |a KXP-PPN1805529285  |e 4142154664 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Prepared by the SPARCL Publications Committee for the SPARCL Investigators: Pierre Amarenco, Julien Bogousslavsky, Alfred S. Callahan, Larry Goldstein, Michael Hennerici, Henrik Sillsen, Michael A. Welch, Justin Zivin","Gesehen am 01.06.2022"],"language":["eng"],"recId":"1805529285","title":[{"title_sort":"Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study","title":"Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study"}],"person":[{"roleDisplay":"VerfasserIn","display":"Amarenco, Pierre","role":"aut","family":"Amarenco","given":"Pierre"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Bogousslavsky, Julien","given":"Julien","family":"Bogousslavsky"},{"given":"Alfred S.","family":"Callahan","role":"aut","display":"Callahan, Alfred S.","roleDisplay":"VerfasserIn"},{"display":"Goldstein, Larry","roleDisplay":"VerfasserIn","role":"aut","family":"Goldstein","given":"Larry"},{"roleDisplay":"VerfasserIn","display":"Hennerici, Michael G.","role":"aut","family":"Hennerici","given":"Michael G."},{"display":"Sillsen, Henrik","roleDisplay":"VerfasserIn","role":"aut","family":"Sillsen","given":"Henrik"},{"family":"Welch","given":"Michael A.","display":"Welch, Michael A.","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Zivin","given":"Justin A.","display":"Zivin, Justin A.","roleDisplay":"VerfasserIn","role":"aut"}],"physDesc":[{"extent":"7 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Basel","dateIssuedDisp":"1991-","publisher":"Karger","dateIssuedKey":"1991"}],"id":{"zdb":["1482069-9"],"eki":["300189834"],"issn":["1421-9786"]},"disp":"Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) studyCerebrovascular diseases","note":["Gesehen am 08.01.2019","Ungezählte Beil.: Supplement"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"300189834","language":["eng"],"pubHistory":["1.1991 -"],"part":{"extent":"7","text":"16(2003), 4, Seite 389-395","volume":"16","pages":"389-395","issue":"4","year":"2003"},"title":[{"title":"Cerebrovascular diseases","title_sort":"Cerebrovascular diseases"}]}],"origin":[{"dateIssuedDisp":"September 19, 2003","dateIssuedKey":"2003"}],"id":{"doi":["10.1159/000072562"],"eki":["1805529285"]},"name":{"displayForm":["the SPARCL Investigators"]}} 
SRT |a AMARENCOPIDESIGNANDB1920